Last reviewed · How we verify
MAL Control.
At a glance
| Generic name | MAL Control. |
|---|---|
| Sponsor | Bispebjerg Hospital |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Actinic keratosis
- Dizziness
- Application site erythema
- Application site pain
- Application site dermatitis
- Post procedural haemorrhage
- Headache
- Application site pruritus
- Fatigue
- Somnolence
- Skin lesion
- Basal cell carcinoma
Key clinical trials
- Novel Coding Strategies for Children With Cochlear Implants (NA)
- Photodynamic Therapy Associated With Sonodynamic Therapy for the Treatment of Nodular Basal Cell Carcinoma (PHASE3)
- A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis. (PHASE1, PHASE2)
- Phase II Clinical Clical of the Pure Protein Derivatives of BCG (PHASE1)
- Surgical Excision Versus Photodynamic Therapy and Topical 5-fluorouracil in Treatment of Bowen's Disease (PHASE4)
- Effects of Voodoo Flossing on Ankle in Participants with Limited Ankle Dorsiflexion (NA)
- Effects of a Floss Band on Ankle in Stroke (NA)
- Methyl Aminolevulinate 8% and 16% Incubated by 1 and 3 for Actinic Keratoses Treatment (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MAL Control. CI brief — competitive landscape report
- MAL Control. updates RSS · CI watch RSS
- Bispebjerg Hospital portfolio CI